New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you manage a DOAC if interested in testing for lupus anticoagulant?

1
4 Answers

Mednet MemberInvited Expert
Hematology · Mayo Clinic

Testing for anti-phospholipid antibodies encompasses two broad categories of testing. One is an ELISA based (aka solid phase) set of tests that include anti-cardiolipin and anti-beta 2 glycoprotein I antibodies. ELISA assay are not affected by DOACs. For the second lupus anticoagulant (aka fluid pha...

How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey

It's challenging to offer specific advice in this situation without knowing a lot more. First, it's important to recognize that CNS involvement by classical Hodgkin lymphoma is extremely rare and strictly requires a brain biopsy to make a diagnosis (even in a patient with active systemic CHL, a seco...

What are the indications for anticoagulation in splenic infarctions?

5
2 Answers

Mednet MemberInvited Expert
Hematology · Medical University of South Carolina

A great reminder that splenic infarct relates to ARTERIAL thromboembolism and not to VENOUS VTE. Too often, I see massive, blind thrombophilia work-up for (incidentally) detected splenic infarcts.

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you approach evaluation for underlying rheumatologic disease in patients with chronic asymptomatic thrombocytopenia?

2
2 Answers

Mednet Member
Rheumatology · University of Chicago

APL testing as well as evaluation for SLE and Sjogrens with complement, urine, antibody testing, not just an ANA.

Would you treat with AZA + venetoclax to achieve CR2 before proceeding to allogeneic stem cell transplant in a young, fit patient with favorable risk AML who relapsed within a year after 7+3 and HIDAC consolidation?

2
1 Answers

Mednet MemberInvited Expert
Medical Oncology · The Ohio State University Comprehensive Cancer Center/James Cancer Hospital and Solove Research Institute

It would be important to know what type of "favorable risk" AML the patients had and also what the current NGS shows. I would wait on NGS results to return to see what the options are first in targeted therapies a potential option. If the patient had Core Binding Factor (CBF) AML, a high dose cytara...

For hypogammaglobulinemia as a complication of successful treatment, do you empirically start prophylaxis with either 400 mg/kg monthly for IVIG or 100 mg/kg weekly for subcutaneous immune globulin?

2
1 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Chicago

Most of the data to support IVIG for hypogam comes from CLL literature. Data in those post-transplant and post-CAR T are limited. IVIG has a reputation of being a bit of a panacea, but I challenge that notion. We investigated the implementation of an IVIG stewardship plan to limit IVIG usage just fo...

How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?

2
1 Answers

Mednet MemberInvited Expert
Hematology · Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital

In general, I favor ropeginterferon as it is FDA-approved and allows for less frequent, every 2-week dosing as compared to peginterferon which is used off-label and requires weekly dosing. However, ropeginterferon is not currently approved for ET and in patients where I decide to use interferon in t...

What are common indications for ordering NGS of peripheral blood?

2
1 Answers

Mednet MemberInvited Expert
Hematology · Johns Hopkins University

I am delighted that someone posed this question because, in my experience as a consultant hematologist, it appears that advances in DNA sequencing technology have outstripped the knowledge base of many practitioners. This is not due to lack of interest or due diligence on their part, but rather beca...

What would you use for cytoreduction in a pregnant patient with high risk ET and APLS?

1 Answers

Mednet MemberInvited Expert
Hematology · Johns Hopkins University

My first instinct in replying to this question is to understand the basis for the diagnosis of “high-risk ET”. Since the patient is pregnant, the basis for the designation “high-risk” must be a history of a prior thrombotic event, either arterial or venous. However, the purveyors of the various MPN ...

Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

It would depend on how long the patient has been on imatinib and the sensitivity of PCR testing. Being able to monitor the p230 transcript at the level of 0.1% or even deeper would be helpful to characterize if the patient has achieved a major molecular response or not. This publication outlines the...